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ABSTRACT 
 
Quality of life is a multidimensional, subjective and individualized concept influenced by culture 
and value systems.  
Cancer as a disease remains a major health problem globally and it’s estimated that 528 000 
women are diagnosed with cervical cancer annually whilst 266 000 will die each year. In Africa 
cervical cancer statistics indicate that there are 99 038 incidences and 60,098 cervical cancer 
related deaths (International Agency for Research in Cancer and World Health Organization, 
2012).  
Women with cervical cancer experience physical, psychological and sex-related problems as 
the consequences of both the disease and treatment and this affects their quality of life. 
Research Question: What is the quality of life of women treated for cervical cancer at an 
academic hospital in Gauteng? 
Purpose of the study was to explore the quality of life in cervical cancer during treatment, at 
six months and twelve months post treatment at an academic hospital in Gauteng. 
Aims of the study: The objectives of the study were (1) to explore the quality of life in cervical 
cancer patients treated with radiation therapy and (2) to compare with the quality of life of 
women at six months and twelve months after completion of treatment at an academic hospital 
in Gauteng.  
Research Design: This is a cross sectional and explorative study. A sample of 153 women 
was recruited using a convenience sampling for the three groups and data were collected using 
the EORTC QLQ-C30 and QLQ-CX24 questionnaires. The data were captured on an excel 
spreadsheet and analysed using SPSS IBM 22.0. 
Results: The overall quality of life of the respondents was affected by the acute side effects 
experienced during treatment. Cancer related symptoms improved with radiotherapy 
treatment. Physical functioning was reported as the most affected domain while social 
functioning was the least affected. 
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CHAPTER 1 
 
OVERVIEW FOR THE STUDY 
 
 
1.0 INTRODUCTION  
This chapter orientates the reader to the study and provides a brief overview of cervical cancer, 
the research problem and question, the objectives of the study and the research methods to be 
used to achieve the objectives. 
 
1.1 BACKGROUND 
Cancer as a disease remains a major health problem globally. According to the Globocan 2012 
statistics (Farley et al. 2012), approximately 14 million people were newly diagnosed with cancer 
and 8.2 million deaths were directly attributed to cancer in 2008. In Africa, the 2008 estimates of 
the incidence of cancer were 846,961 and the mortality 591,169; South Africa had an estimated 
incidence of 77,440 and a mortality rate of approximately 47,350. Cervical cancer has become 
the fourth most common cause of mortality amongst women of reproductive age in the world. It is 
estimated that 528,000 women are diagnosed with cervical cancer annually, whilst 266,000 will 
die from this disease each year. In Africa, cervical cancer statistics indicate there are 99,038 
incidences and 60,098 cervical cancer-related deaths annually. This is the second highest 
mortality rate after breast cancer in Africa. According to the Cancer Association of South Africa 
(CANSA 2015), there were 5,433 histologically diagnosed cervical cancers in 2010. In addition, 
cervical cancer was the leading cause of cancers deaths in females with 3,498 women dying from 
this disease (Herbst 2014). 
 
Cervical cancer is a preventable disease and detection at an early stage is associated with 
excellent survival, however, most women in developing countries present with advanced and 
often terminal disease (Denny 2012). Many women are diagnosed between the ages of 25 and 
64 years when they are at the peak of their productive lives, careers and family life(Kumar et al. 
2014) and face various challenges. According to Pasek et al. (2013), women face a time of 
depression, anxiety and worry over the outcomes of the disease and the possibility of loss of life. 
During treatment with radiotherapy the women experience various side effects such as fatigue, 
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radiotherapy induced skin changes, vaginal stenosis leading to dyspareunia and pelvic, bone and 
back pain. Ancuța et al. (2012) noted that the physical, psychological and sexual problems women 
with cervical cancer experience, as a consequence of both the disease and treatment, have 
negative influence on their quality of life.  
 
Quality of life is a multidimensional concept (Goker et al. 2011; Du Toit 2013; Maree & Jansen 
Van Rensburg 2015) and there is no common definition or standard of measurement (Ferrans 
1990). The multi-dimensional aspect of quality of life, according to Cella (1994), refers to the broad 
coverage of content which includes physical, functional, emotional and social wellbeing. The 
World Health Organization defines quality of life as “an individual’s perception of their position in 
life in the context of the culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns.”(Vaz et al. 2007pg. 584) 
  
1.2 RESEARCH PROBLEM AND QUESTION 
Little is known about the quality of life in women treated for cervical cancer in Africa. Although the 
quality of life of women living with cervical cancer has been explored, these studies originate 
primarily from countries such as Poland (Barnaś et al. 2012), Romania (Ancuța et al. 2012) and 
China (Zeng et al. 2010). It also seems as if this topic has not been explored on the African 
continent as no literature could be found. The research question for the study was therefore: What 
is the quality of life of women treated for cervical cancer at an academic hospital in Gauteng? 
 
1.3 PURPOSE AND AIMS OF THE STUDY 
The study aimed to explore quality of life in women diagnosed and treated for cervical cancer. 
• whilst being treated with radiotherapy, at six months after completion of treatment and at 
twelve months after treatment at an academic hospital in Gauteng, and  
• to compare the quality of life of these three groups of women 
  
1.4 RESEARCH SETTING AND METHODS 
The research setting was an academic hospital in Johannesburg which offers specialised care to 
cancer patients. This was an exploratory cross sectional study. The study population consisted of 
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all women diagnosed with cervical cancer and were either receiving treatment at the academic 
hospital or had completed treatment six or twelve months prior to the investigation. Convenience 
sampling was used to select a calculated sample of 153 (n=153) based on an estimate that 
approximately 662 to 721 women are treated annually for cervical cancer (Msadabwe 2009). 
Structured interviews were used to collect data. The EORTC QLQ-C30 (version 3) (Appendix A) 
and EORTC QLQ CX24 (Appendix B) were used as data collection instruments. Data were 
captured on an Excel spreadsheet and imported to an SPSS IBM 22.0 computer programme for 
analysis. Descriptive statistical analysis was used to analyse socio-demographic variables and 
the Kruskal-Wallis test compared the mean responses of the different study groups. Data were 
analysed under the supervision of a statistician. 
 
1.5 OPERATIONAL DEFINITIONS 
Radiotherapy: Radiotherapy involves the use of ionising radiation directed at the tumour with the 
aim of damaging and destroying the cancer cells. Radiotherapy is one of the treatment methods 
used in cervical cancer (World Health Organization 2006). 
Screening: This is an intervention provided to asymptomatic target populations aimed at 
identifying the people at risk of developing the disease or any predisposing factors(World Health 
Organization 2014) 
Side Effects: Side effects are undesirable effects that resulting from disease and/or treatment. 
Some side-effects some could clear shortly after completion of treatment while others may persist 
for longer times (World Health Organization 2006).  
 
1.6 CHAPTERS OF THE STUDY 
The study will be presented as follows: 
Chapter 1. Overview for the study 
Chapter 2. Literature Review 
Chapter 3. Research designs and Methods 
Chapter 4. Findings 
Chapter 5. Discussion and conclusion 
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1.7 SUMMARY 
In summary, this chapter introduced cervical cancer as a global health problem, presented the 
problem statement and question, the objectives of the study, the research method used to answer 
the research objectives and the operational definitions. 
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CHAPTER 2 
LITERATURE REVIEW 
 
 
2.0 INTRODUCTION 
Chapter 1 presented an overview for the study. In Chapter 2, the researcher addresses cervical 
cancer as a worldwide health problem. Cervical cancer is further discussed in relation to risk 
factors, prevention and early detection, diagnosis and staging, treatment and prognosis. In 
addition, quality of life, the various views relating to this phenomenon, the various domains that 
affect quality of life, measurement of quality of life and quality of life in cancer and finally cervical 
cancer women, will be discussed.  
  
2.1 CANCER AS WORLD WIDE HEALTH PROBLEM  
According to the 2008 statistics from Globocan (Ferlay et al. 2014), it is estimated that 14 million 
people globally were newly diagnosed with cancer, whilst 8.2 million died of this group of diseases. 
Cervical cancer was the seventh most common cancer overall and fourth amongst the cancers in 
women. In Africa, the estimates of the newly diagnosed with cancer was 846,961 and the deaths 
associated with cancer were estimated at 591,169. South Africa has an estimated 77,440 newly 
diagnosed people with cancer and 47,350 deaths from cancer (Farley et al. 2012).  
  
In the world, it is estimated that 527,624 women were newly diagnosed with cervical cancer and 
265,672 of them died of the disease during 2008. Africa had an estimated 99,038 women newly 
diagnosed and 60,098 deaths, which accounted for 22.6% of the global deaths related to cervical 
cancer. The Cancer Association of South Africa (2014) reported that cervical cancer was the 
leading cause of cancer deaths in women, estimated at 3,498 in 2000. However, the 2009 South 
African Cancer Registry reports that 5,270 women were histologically diagnosed with cervical 
cancer in the same year (Herbst 2015). 
 
 
6 
 
2.2 DESCRIPTION OF CERVICAL CANCER 
Cervical cancer is a disease that forms in the cells of the cervix.  The two main types of cells 
covering the cervix are squamous cells at the ectocervix and glandular/columnar cells at the 
endocervix. These two cell types join at the squamocolumnar junction, also called the 
transformation zone. Most cervical cancers develop in the transformation zone and usually grow 
gradually in a multi-stage process from a pre-cancerous lesion to a cancerous tumour (World 
Health Organization 2014). 
 
2.2.1 Risk Factors 
The exact cause of cervical cancer is not known, but persistent infection of the cervix with human 
papilloma virus (HPV)has been recognised as the leading cause (Denny 2012). The World Health 
Organization (WHO 2014) states that the untreated HPV infection takes 10 to 20 years to progress 
from pre-cancerous lesions to cancer. Many other factors predispose the development of cervical 
cancer such as, smoking, immunosuppression, multi-parity of more than five children, early onset 
of sexual intercourse, multiple sexual partners, untreated human immunodeficiency virus (HIV) 
infection and a family history of cervical cancer(World Health Organization 2014). 
 
2.2.2 Prevention and early detection 
Denny (2012) states that since HPV play an important role in cervical cancer development. 
Prevention and early detection is key in the prevention of cervical cancer. Prevention and early 
detection strategies are either primary or secondary. Primary prevention entails the HPV 
vaccination of girls between the age 9 to 13 years before they are sexually active, as well as sex 
education to both boys and girls to delay initiation of sexual activities and the reduction of risk 
factors mentioned earlier that predispose to HPV transmission (WHO 2014). 
 
Secondary prevention targets asymptomatic women aged between 30 to 49 years and involves 
screening and identifying pre-cancer lesions (WHO 2014). In addition, the WHO (2014) further 
recommends treating women in the pre-cancerous stage before the lesions progress to invasive 
cancer. Various methods are used to screen women for cervical cancer. For instance, the 
International Atomic Energy Agency (IAEA 2012) suggests the use of visual inspection with acetic 
acid (VIA) and visual inspection with Lugol’s Iodine (VILI) in resource limited countries. Women 
who are VIA or VILI positive should be treated with cryotherapy.  However, those with lesions 
suspicious for cancer should be sent for colposcopy and biopsy.   
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Symptoms of invasive cervical cancer are broadly divided to two categories - early and advanced 
- based on  the severity (World Health Organization 2014). Early symptoms include: foul smelling 
vaginal discharge, post-menopausal bleeding, post-coital spotting or bleeding and any irregular 
bleeding in women of reproductive age. Advanced symptoms include backache, weight loss, 
lower abdominal pain, urinary frequency and urgency, swelling of lower limbs, breathlessness 
and vesical vaginal fistula (World Health Organization 2014). 
 
2.2.3 Cervical cancer diagnosis and staging 
According to the WHO (2006), conclusive diagnosis of cancer is by histopathological examination 
of tissue taken from the suspicious lesion and should be done before commencement of any 
therapy.  Various techniques could be used to biopsy suspicious cervical lesions for example, 
conventional cytology, HPV DNA testing and visual inspection methods with vinegar or Lugol’s 
solution (World Health Organization 2006).  
  
Cervical cancer staging is based on tumour size and the metastasis to the pelvis region and 
distant organs (World Health Organization 2006). Various systems are available but the 
recommended one for cervical cancer was developed by The International Federation of 
Gynaecology and Obstetrics (FIGO)(World Health Organization 2006),which is presented in 
Table 2.1. 
 
Table 2.1 The FIGO Staging 
Stage Description 
I Cervical carcinoma confined to the cervix. 
IA This is the earliest form of stage 1. There is very small amount of 
cancer that can only be seen under a microscope. 
IA1 The area of invasion is less than 3mm deep and less than 7mm 
wide. 
IA2 The area of invasion is between3mm and 5mm deep and less 
than 7mm wide. 
IB  Clinically visible lesions limited to the cervix uteri or preclinical 
cancers greater than stage IA. 
IB1 Clinically visible lesion less than 4.0 cm in greatest dimension. 
IB2 Clinically visible lesion greater than 4.0 cm in greatest dimension. 
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II Cervical carcinoma invades beyond the uterus but not to the 
pelvic wall or to the lower third of the vagina. 
IIA Without parametrial invasion. 
IIA1 Clinically visible lesion less than4.0 cm in greatest dimension. 
IIA2 Clinically visible lesion greater than 4.0 cm in greatest dimension. 
IIB With obvious parametrial invasion. 
III The tumour extends to the pelvic wall and/or involves lower third 
of the vagina and/or causes hydronephrosis or non-functioning 
kidney. 
IIIA Tumour involves lower third of the vagina with no extension to the 
pelvic wall. 
IIIB Extension to the pelvic wall and/or hydronephrosis or non-
functioning kidney. 
IV The carcinoma has extended beyond the true pelvis or has 
involved (biopsy proven) the mucosa of the bladder or rectum. A 
bullous oedema, as such, does not permit a case to be allotted to 
stage IV. 
IVA  Spread of the growth to adjacent organs. 
IVB Spread to distant organs beyond the pelvic area. 
Source: Adapted from the FIGO committee of Gynecologic Oncology 
 
2.2.4 Treatment  
Cervical cancer can be treated by means of surgery, radiotherapy which includes both external 
beam radiation and brachytherapy and with or without concomitant chemotherapy (IAEA 2013). 
The IAEA (2013), guiding the management of women with cervical cancer in resource restricted 
care settings, is of the opinion that every woman without metastatic disease should be treated as 
aggressively as can be tolerated to improve her chances of being cured. Patients with metastatic 
disease should receive palliative treatment and care.  
 
Women with early cervical cancer can be treated with surgery, external beam radiation and 
brachytherapy, those with stage IB2 to IIA2 cervical cancer can also be treated by means of 
surgery, whilst those with Stage IIB to IVA and not candidates for surgery can be treated with the 
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standard treatment of external beam radiation, brachytherapy with or without concomitant 
chemotherapy. Cisplatin is commonly used as concomitant chemotherapy drug (IAEA 2013), 
however treatment is mainly dependent on patient factors such as the patient’s medical condition, 
presence of other co-morbidities, age, nutritional status and the physician’s judgment alongside 
the availability of treatment modalities (IAEA 2013). 
 
Women treated for cervical cancer experience various side effects which could have a negative 
influence on their quality of life as side effects can last for months and even years after treatment. 
Early effects occur during radiotherapy or immediately after radiotherapy and affect tissues that 
are rapidly multiplying, for example the mucosa, bone marrow, gastrointestinal tract and skin, and 
soon heal after completion of radiotherapy. Sub-acute effects occur in a few weeks to months 
after radiotherapy, while the late effects occur months to years after radiotherapy and affect 
tissues that are slow proliferating, for example the tissue of the kidneys (Joanne 2015). 
 
2.3.5 The prognosis for women diagnosed with cervical cancer 
The prognosis for women diagnosed with cervical cancer depends on the stage at which 
diagnosis is made (Sankaranarayanan et al. 2010). Sankaranarayanan et al. (2010) observed 
that the survival of women with cervical cancer was influenced mainly by the availability, 
accessibility and development of health care services to enable early detection and treatment. 
Countries such as Hong Kong and Singapore have well established screening, diagnosis and 
treatment programmes and therefore a higher five year survival rate (63% to 79%)compared to 
less developed countries in sub-Sahara Africa, such as Uganda which has a less than 13% five 
year survival rate (Sankaranarayanan et al. 2010). A five year survival with ideal treatment is 
estimated highest at 98% for stage IA and lowest >5% for stage IVB (World Health Organization 
2006). 
 
Other prognostic indicators are the patient’s performance status, FIGO stage and lymph node 
status (Kosary 1994; Xiao et al. 2015). Pre-treatment anaemia and nutritional status were 
prognostic indicators observed by Xiao et al. (2015). 
 
2.3 QUALITY OF LIFE 
Quality of life is a multidimensional concept (Goker et al. 2011; Du Toit 2013; Maree & Jansen 
Van Rensburg 2015) and there is no common definition or standard of measurement (Ferrans 
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1990). The multi-dimensional aspect of quality of life, according to Cella (1994), refers to the broad 
coverage of content which includes physical, functional, emotional and social wellbeing. Ferrans 
(1990) views the multidimensionality of quality of life as the ability to lead a normal life, happiness 
and satisfaction, achievement of personal goals, social utility and natural capacity. Maree and 
Cella (1994) both agree on the concept of quality of life being subjective. Subjectivity refers to the 
fact that quality of life judgement can only be made by the individual (Maree & Jansen Van 
Rensburg 2015), furthermore patients in the same situation and stage of illness can rate their 
quality of life differently, being good or poor.   
 
The World Health Organization defines quality of life as “an individual’s perception of their position 
in life in the context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns” (Vaz et al. 2007). Culture has a set of beliefs, values 
and practices which are unique to each group. In addition, culture is an important determinant of 
quality of life as it expresses the purpose and meaning of life in sickness and in health (Kagawa-
Singer et al. 2010) 
 
Kagawa-Singer et al. (2010) had an example of Japanese–Americans who had the view that side 
effects of treatment, as expected outcomes, were to be endured to maintain family harmony, while 
Anglo-Americans perceived it as a problem to be overcome. However, Zeng et al. (2010) 
observed that cultural differences among cancer survivors has led to different interpretations of 
the concept of quality of life. 
 
Quality of life has become an important consideration in evaluating the effectiveness of healthcare 
and particularly significant in the field of cancer care, where treatments are often incapacitating 
butat the same time long-term survival is increasing (Pilkington & Mitchell 2004). Goker et al. 
(2011) indicates that cancer itself causes co-morbid symptoms and treatment strategies are also 
debilitating by decreasing cardio-respiratory capacity, pain, fatigue and suppressing immune 
function, thus all aspects of life are affected negatively. 
 
Cancer can dramatically change a person’s life, in particular, gynaecologic cancer and its 
treatment which are thought to affect women’s experience of themselves as sexual beings 
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(Pilkington & Mitchell 2004). Women treated for cervical cancer reported physical, emotional, role 
domains and financial difficulties at different stages of treatment (Pasek et al. 2013). Ancuta et al. 
(2012) note that women with cervical cancer experience physical, psychological and sex-related 
problems as the consequences of both the disease and treatment and this affects their quality of 
life. 
 
2.4 DOMAINS OF QUALITY OF LIFE 
The domains of quality of life also seem to be a complex issue. For instance, Kuyken and group 
(1995), in the World Health Organization quality of life assessment (WHOQOL), identified six 
domains which form the quality of life namely: physical domain, psychological domain, level of 
dependence, social relationships, environment and spiritual beliefs. Pearman (2003) and Cella 
(1994), in contrast, referred to only four domains namely: physical, functional, emotional and 
social domains. Maree and Jansen Van Rensburg (2015) also identified four domains: health and 
physical functioning, psychological/spiritual, social and economic and family. In contrast, Ashing-
Giwa (2005) identified two levels of paradigms: individual and systemic, with each consisting of 
four domains. The individual level consists of general health, medical factors, health efficacy and 
psychological well-being domains; the systemic level is composed of: social-economic, cultural, 
and demographic and health system domains. 
 
2.4.1 The physical domain 
The physical domain refers to perceived and observed physiological changes which patients 
experience and represents a combination of disease symptoms, treatment-related side effects 
and general physical wellbeing, as perceived by the patient  Women living with cervical cancer 
experience various disease and treatment related symptoms, not only during treatment but also 
after completion of treatment. Examples of such symptoms include pain, nausea and fatigue (Vaz 
et al. 2011).  Pain is subjective and can either be acute, lasting less than three months or chronic, 
lasting more than three months (Joanne 2015). 
 
Fatigue, described by The National Comprehensive Cancer Network (NCCN 2015) as "a 
distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or 
exhaustion related to cervical cancer or cancer treatment that is not proportional to recent activity 
and interferes with usual functioning,” may be caused by poor nutrition, pain, anaemia, stress, 
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depression and some drugs such as chemotherapy. Physical exhaustion, fatigue and a general 
feeling of tiredness and weakness are some of the symptoms experienced by women while 
undergoing treatment for cervical cancer (Pasek et al. 2012; Klee et al. 2000). 
 
Klee et al. (2000) and Kumar et al. (2014) observed that some women who were treated for 
cervical cancer while undergoing radiotherapy experienced nausea, vomiting, diarrhoea and loss 
of appetite; however, diarrhoea may persist for up to twelve months after treatment. Maher & 
Denton (2008) noted that the main source of anguish for the women treated for cervical cancer 
was diarrhoea and faecal urgency, or incontinence, as it causes discomfort in public places and 
they have to remain confined to the house feeling socially isolated. In addition, constipation was 
reported at some point while undergoing treatment and during follow up ( (Pasek et al. 2013). 
Radiotherapy-induced proctitis, bloating, flatulence, enteritis and proctopathy have also been 
reported by women treated for cervical cancer (Kuku et al. 2013), whilst some experienced rectal 
bleeding resulting from ulceration, easily damaged blood vessels or stenosis in the bowel (Kuku 
et al. 2013; Pfaendler et al. 2015). 
 
The urinary system is also affected and the women treated for cervical cancer experienced urine 
incontinence, radiology-induced cystitis,  haematuria, urinary frequency and dysuria (Klee et al. 
2000;Maher & Denton 2008; Pfaendler et al. 2015).  
 
Damage to the lymphatic vessels can be caused by either the disease obstructing the lymphatic 
system or alteration of the connective tissues by radiotherapy, leading to retention of lymphatic 
fluid causing lymphedema of the lower extremities. Women living with lymphedema present with 
swelling of the feet, leg heaviness and discomfort, skin texture changes and feel tight and tingling 
sensations in the legs limiting their ability to perform daily tasks or work thus affecting negatively 
the quality of life (Pfaendler et al. 2015). 
Sexual health is an important determinant in the quality of life in women, yet up to 65% of women 
treated with radiotherapy experience one or more sexual problems (Maher & Denton 2008). In 
addition, women experience physical side effects, such as lack of lubrication and decreased 
sexual interest, and menopausal symptoms such as hot flushes (Maher et al. 2008; Barnaś et al. 
2012; Kumar et al. 2014). Vaginal stenosis (shortening of the vagina), which develops between 
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three to six months after treatment, leads to dyspareunia which leads to other problems such as 
inelastic vaginal tissue and tendency to experience pain and bleeding during sexual intercourse 
(Greime et al. 2008; Ancuța et al. 2012). All these changes compound and cause the women to 
have reduced desire for sex, arousal and orgasm (Barnaś et al. 2012). 
 
2.4.2 The Psychological and Socioeconomic Domains 
Psychosocial domain includes the need to be cherished, to have friends, to be treated with dignity 
and respect and role fulfilment (Maree & Jansen Van Rensburg 2015). In addition, the economic 
domain consists of the ability to provide for basic commodities and food (Maree & Jansen Van 
Rensburg 2015).  
  
Raoof et al. (2015) observed that emotional domain was least affected and could be related to 
the unity of people, which is characterised by intimate and close relationships between family 
members, friends and neighbours; most of them are living amongst extended families. Social 
support includes the presence of a strong family network and community support system which 
provides positive social and emotional support to women treated for cervical cancer Adequate 
social support has led to improved quality of life, whereas a lack of social support has led to poor 
quality of life and a higher death rate (Ashing-Giwa 2005). 
 
Ashing-Giwa (2005) describes the socioeconomic status as level of education, income and 
employment status. Ashing-Giwa (2005) further goes on to observe that socioeconomic status is 
closely linked to the quality of health and an identifiable risk to poor quality of life. Financial 
problems are a challenge faced by most women in Africa and the cost of treatment compounds 
the existing poor economic status. Inability to perform exhausting activities while undergoing 
treatment and during convalescence, or resuming work for those who were employed, increased 
the financial burden affecting the quality of life negatively Upon diagnosis of cervical cancer, 
women may experience depression and the possible outcomes and possibly loss of life. Klee et 
al. (200b) observed that depression and anxiety scores were high initially, at the time of diagnosis, 
but decrease over time as the women living with cervical cancer went through psychological 
adaptation to cope with the effects on everyday life. 
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Pasek et al. (2012), Klee et al. (2000b) and Maher & Denton (2008) all agreed that correct 
information and communication enables women to have better coping abilities toward the disease. 
Maher & Denton (2008) write out the and  further acknowledge the importance of psychosocial 
interventions aimed at improving the psychosocial functioning, for example relaxation techniques 
and counselling sessions by a member of the health care team. 
 
2.5 MEASURING QUALITY OF LIFE 
Measuring quality of life is a standardised way of describing the effect of disease and its treatment 
and is based on the patient’s own rating of simple questions. In addition, Klee et al. (2000) 
provides an overview of how and to what degree a disease and its treatment affect the lives of 
the patients. Besides the evaluation of the treatment toxicities, quality of life reflects the patients’ 
perspective (Klee et al. 2000). Pearman (2003) observed that until recently, treatment for 
gynaecologic cancers has focused almost entirely on prolongation of life and few research studies 
have sufficiently addressed issues related to quality of life. 
 
Kaasa and Loge (2003) divide quality of life assessment instruments into three categories: generic 
instruments, disease-specific instruments and domain-specific instrument. Generic instruments 
are not specific to any population or disease and are therefore applicable to patients living with 
more than one condition. In addition, generic instruments allow for comparisons across 
populations and conditions (Maree & Jansen Van Rensburg 2015). The disease-specific 
instruments are developed for specific groups of patients, for instance, the European Organization 
for Research and Treatment of Cancer (EORTC-QLQ-C30) was developed for cancer in general, 
whilst the EORTC Quality of Life questionnaire (EORTC QLQ-CX24),cervix cancer site-specific 
instrument, was developed for patients with cervical cancer (Zeng et al. 2010). Domain-specific 
instruments assess the specific domain that comprise overall quality of life, for example pain, 
anxiety, fatigue and psychological distress. 
 
The most widely used cancer-specific instruments are the EORTC QLQ-C30 and FACT-G 
(Functional Assessment of Cancer Therapy-general). The EORTC QLQ-C30 consist of 30 items 
and includes five functional domain scales namely: physical, role, cognitive, emotional and social 
functions along with disease specific symptoms, dyspnoea, loss of appetite, insomnia, 
constipation and diarrhoea and perceived financial implications of the disease (Aaronson et al. 
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1993). The FACT-G is composed of 27 items and covers primarily four domains: physical, 
emotional, social and functional wellbeing (Zeng et al. 2010).  
 
2.6 SUMMARY 
In summary, cervical cancer has been presented as a major health problem affecting women 
worldwide. Quality of life is subjective and multidimensional.  The quality of life has in the past not 
received much attention (Pearman 2003) and yet cervical cancer affects all domains 
(psychological, functional, social, sexual, physical and financial) of women’s life. 
The next chapter will describe the research methods. 
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CHAPTER 3 
RESEARCH DESIGN AND METHODS 
 
 
3.0 INTRODUCTION 
The previous chapter presented cervical cancer as a major health problem and described quality 
of life.  In this chapter the research design and methods will be discussed. 
 
3.1 RESEARCH DESIGN 
This was an exploratory and cross-sectional study. A cross sectional study is a design which 
seeks to examine the respondents at various stages of development simultaneously; exploratory 
design is conducted when little is known about the topic of interest in a given population (Burns & 
Grove 2011). This is applicable to the study as the researcher examined the respondents on 
treatment, at six months and twelve months after treatment with radiotherapy simultaneously   
 
3.1.1 Study Setting 
Burns and Grove (2011) described a setting as the location in which a study was conducted. It 
paints a picture and gives clarity of where and how the study was conducted. The study setting 
was an academic hospital which serves as a referral centre for many hospitals in Gauteng 
Province.  
 
The academic hospital had a bed capacity of 1,088 beds, more than 4,000 professional and 
support staff and serves as a referral hospital to a number of hospitals in its referral chain in the 
Gauteng Province. The hospital has twelve clinical departments, one of which is radiation therapy. 
The radiation therapy department offers outpatient services to stable patients, whilst those who 
are very ill and require continuous monitoring are admitted to the inpatient wards. The radiation 
therapy department has several clinics for all cancers that are operational on assigned days of 
the week to provide holistic care to cancer patients.  
 
The research study was carried out at the gynaecology clinic which offers specialised care to 
women with cervical cancer at different stages for the entire course of treatment with radiotherapy. 
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The gynaecology clinic is operational five days a week and the patients on radiotherapy treatment 
are seen by the oncologists on weekly basis until they complete their treatment. Upon completion 
of the radiotherapy, the women are booked for appointments every three months for the first two 
years, then every six months for another two years, then once yearly for five years. It is 
approximated that 662 to 721 women are treated annually (Msadabwe 2009) at the gynaecology 
clinic. The International Atomic Energy Agency has identified the department as a resource centre 
for training. 
 
3.2 RESEARCH METHOD 
Burns and Grove (2011) describe the research method as the operational approach of the study 
which includes the sample and sampling techniques, population, setting, methods of data 
gathering and analysis. 
 
3.2.1 Population and sampling 
The population is referred to as the individuals who meet the criteria the researcher is interested 
in studying (Brink et al. 2013).In this study, the population were all women diagnosed with cervical 
cancer and were either on treatment or have completed treatment six or twelve months prior to 
the investigation at the radiation department of the specific academic hospital. 
Convenience sampling was used to select a sample of 153 respondents meeting the following 
inclusion criteria:  
• The patient diagnosed with cervical cancer and undergoing treatment with radiotherapy 
with or without chemotherapy, alternatively six or twelve months post treatment. 
• Older than eighteen years. 
• Willing to participate. 
According to Burns and Grove (2011), convenience sampling refers to the use of respondents 
who happen to be in a given place at a particular time and can provide a desired sample size. In 
addition, convenience sampling is commonly used in health related studies. The sampling 
technique was appropriate for the study as the respondents were all at the radiation therapy 
department at the time of the study. The sample size was calculated using finite population 
correction. 
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no= initial sample=157 
 N= Target population =7,735 
  n= 
𝑛𝑜
{1+[
𝑛𝑜−1
𝑁
]}
 
  n= 
157
{1+[
157−1
7735
]}
 
  n=153 
 
The total sample was determined as 153 (n=153) to achieve a confidence level of 95%. The total 
sample consisted of three samples of 51(n=51) : one sample for during treatment, another at six 
months and at twelve months post treatment.  
 
The respondents, those waiting for treatment and those on follow up waiting to see the oncologist, 
were recruited whilst in the waiting bays. All women were invited indiscriminately and the 
consenting ones were given the information sheet to read then the consent form to sign once they 
had understood the research study. A total of 189 women were recruited, but 23 were found not 
to be within the study criteria, on treatment, at six months or twelve months, whilst 13 were 
excluded due to language barriers.  
  
3.2.2 Data Gathering 
Data gathering is defined by Burns and Grove (2011) as the precise, systematic collection of 
information that is relevant for the specific research objectives in the study. Structured interviews 
were used to collect data. This involves the use of a structured instrument and all respondents 
are asked the same questions in the same order (Polit and Beck 2012). The researcher built 
rapport and provided privacy during the structure interviews in order to enhance genuineness in 
respondents’ responses to the interview questions. The researcher also informed the respondents 
that there are no write or right answers. The researcher, a female registered nurse, administered 
the instruments, the devices the researcher uses to gather the relevant data (Brink et al. 2013), 
during a structured interview in a quiet and private room, in English. 
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Two instruments were used to gather data: EORTC QLQ-C30 (version 3) and EORTC QLQ CX24. 
Permission was sought to use the instruments (Annexure C). The EORTC QLQ-C30 (version 3) 
assesses quality of life in all cancer patients, while EORTC QLQ CX24 is specific to cervical 
cancer. Both instruments have been used widely in studies pertaining to cervical cancer thus 
allowing for comparison of findings.  
 
The EORTC QLQ-C30 instrument uses two Likert scales: 4 point and 7 point. The first part 
consists of 28 questions measuring the functional and symptom domain and has a 4 point Likert 
scale, where 1 indicates not at all, 2 a little, 3 quite a bit and 4 very much. Questions 29 and 30 
have a 7 point Likert scale to assess the overall quality of life with 1 indicating very poor and 7 
being excellent. 
 
All the scales and single-items measure range in score from 0 to 100. A high score represents a 
corresponding functional, global health status or symptomatology. Thus a high score for a 
functional scale represents a high / healthy level of functioning; a high score for the global 
health status / QoL represents a high QoL, but a high score for a symptom scale / item 
represents a high level of symptomatology / problems 
 
The EORTC QLQ-C30 is divided into three parts namely: functional, symptomatic and global 
health status. The functional domain is further divided into five parts: (1) Physical domain which 
is assessed in questions1 to 5, (2) Role functioning domain in questions 6 and 7 (3), Emotional 
functioning in questions 21 to 24 (4), Cognitive functioning are questions 20 and 25 and (5) Social 
functioning are questions 26 and 27.  
 
Symptom domain scores are divided into nine parts: (1) Fatigue is assessed using questions 10, 
12 and 18. (2) Nausea and vomiting are questions 14 and 15, (3) Pain are questions 9 and 19, 
(4) Dyspnoea question8, (5) Insomnia is question 11, (6) Appetite loss is question 13, (7) 
Constipation is question 16, (8) Diarrhoea is question 17 and (9) Financial difficulties is questions 
28. Overall global health status is assessed using questions 29 and 30.  
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The EORTC QLQ-CX24 instrument has a 4 point Likert scale where 1 indicates not at all, 2 a 
little, 3 quite a bit and 4 very much. The EORTC QLQ-CX24 is divided into two parts namely: 
functional domain and symptom domain. Functional domain are further divided into four sub 
sections (1) Body image represented by variables -questions 45 to 47, (2) Sexual activity is 
question 49, (3) Sexual enjoyment is question 54 and (4) Sexual/vaginal functioning are questions 
50 to 53. Symptom scores is divided to five sub sections (1) Symptom experience represented by 
questions 31 to 37, 39 and 41 to 43, (2) Lymphedema is question 38, (3) Peripheral neuropathy 
is question 40, (4) Menopausal symptoms is question 44 and (5) Sexual worry is question 48.  
 
The respondent’s demographic information on the stage of the cervical cancer was extracted from 
the clinical records by the researcher. The age, employment status and marital status were 
provided by the respondent to the researcher. The demographic information was recorded on the 
information sheet attached (Appendix D). 
 
 Dependent variable is described as the outcome the researcher wants to predict, while the 
independent variable is the activity that is varied by the researcher to create an effect on the 
dependent variable (Burns & Grove 2011). The dependent variables were the scores of the two 
instruments used (EORTC QLQ-C30 (version 3) and EORTC QLQ CX24). The variables include, 
physical functioning, role functioning, emotional functioning, social functioning, cognitive 
functioning and overall quality of life. The independent variables were, age, marital status, 
employment status and the stage of disease at the time of diagnosis. 
 
3.2.3 The planning for the data gathering 
Plan for data gathering began by first getting approval of the study topic by the Faculty of Health 
Science. Permission from The European Organization for Research and Treatment of Cancer 
Quality of Life Group was sought to use the instruments for data gathering. The research protocol 
was peer reviewed and consequently approved by the Human Research Ethics Committee 
(Medical) of the Faculty of \health Sciences, University of Witwatersrand. Permission from the 
Chief Executive Officer of the academic hospital was sought to allow the research study to be 
conducted in her facility. 
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The women who met the inclusion criteria were invited to participate in the study by explaining to 
them the process involved in data gathering and that they had the right to refuse to participate or 
to withdraw at any point of the study without losing their entitled benefits. Consenting respondents 
signed the information sheet and the consent form and the researcher signed as the witness.  
 
3.3 DATA ANALYSIS 
Burns and Grove (2007) define data analysis as the technique of reducing, organising and giving 
meaning to data. Data that was captured on an Excel spreadsheet was imported to an SPSS IBM 
22.0 computer programme for analysis. According Polit & Beck (2012), descriptive statistics are 
used to describe and synthesise data. Descriptive statistical analysis was used to analyse socio-
demographic variables and presented using measures of central tendency: mean, mode, median 
and in tables and the Kruskal-Wallis test to compare the mean responses of the different study 
groups. Data was analysed under the supervision of a statistician. 
 
The scoring tool for both instruments was provided by the European Organization for Research 
and Training on Cancer Quality of Life Group and was divided into three parts: global health 
status, functional scales and symptomatic scale. The raw scores are standardised to linear 
transformation grades which range from 0 to 100. The higher the functional scores reported 
indicated a better functioning status. In contrast, a higher score reported on the symptom score 
indicated more problems affecting quality of life. The higher the scores in the overall global health 
status indicated a better quality of life. 
 
3.4 VALIDITY AND RELIABILITY 
According to Polit and Beck (2012), instrument validity seeks to ascertain whether it accurately 
measures what it is supposed to measure. The instruments used in the study were validated in 
Europe between 2003 and 2005, using 346 women in nine countries by the European 
Organization for Research and Treatment of Cancer Quality of Life Group (Aaronson et al. 1993). 
The QLQ C-24 validation and translation was carried out at the Unit of Gynaecology and Oncology 
at Tygerberg Hospital using cervical cancer patients and is available in isiXhosa and Afrikaans 
(Du Toit & Nel 2012). 
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Reliability is the degree of consistency and dependability with which an instrument measures the 
variables it is designed to measured (Polit & Beck 2012). In this study the same instruments were 
used on all patients to ensure consistency of the instrument. 
 
3.5 ETHICAL CONSIDERATIONS 
Burns and Grove (2011) explain that ethics consist respect for people, beneficence and justice. 
In order to protect and respect the rights of the respondents who consented to take part in the 
study the following steps were taken: 
• The research proposal was presented to the Department of Nursing Education for peer review. 
• The research proposal was submitted to the School of Therapeutic Sciences Postgraduate 
Committee for permission to conduct the study. 
• The proposal was submitted to the Human Research Ethics Committee (Medical), of the 
University of the Witwatersrand, for ethics approval (Ethics Clearance Certificate Number 
M150441). 
 
•  The Chief Executive Officer (CEO) of the academic hospital in which the study was conducted 
(Annexure E) approved the study. 
• Respondents who agreed to participate in the study were given detailed information on the 
study were given a chance to ask questions and to seek clarifications. Respondents were 
assured that their participation was voluntary and they could withdraw from the study at any 
point with no penalty. 
• Respondents were required to sign an informed consent form (Annexure G) individually prior 
to participating in the study. 
• Confidentiality and anonymity of respondents was promoted by the use of respondent’s codes 
during data collection 
 
3.6 SUMMARY 
In conclusion, this chapter has sought to explain the research design and method used, the 
population and sampling criteria and data gathering and data analysis. Issues of ethical 
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considerations and validity and reliability were covered in this chapter. The results of the study 
will be presented in Chapter 4.  
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CHAPTER FOUR 
RESULTS OF THE STUDY 
 
 
4.0 INTRODUCTION 
The previous chapter presented the research design and method used in the study; this chapter 
will present the findings of the study.  
 
4.1 DEMOGRAPHIC DATA 
The ages of the sample (n=153) ranged from 30 to 79 years, with a mean age of 50.6 years 
SD ±11.9. Nearly half the sample 46.4%; (n=71) were single and unemployed (48.4%; n=74) and 
26.1% (n=40) suffered from stage IIIA disease. The demographic information is presented in 
Table 4.1; m0 refers to during treatment, m6 to 6 months after treatment and m12 to 12 months 
after treatment.  
Table 4.1 Demographic characteristics of the respondents (n=153) 
Variables M0 
n=51 
M6 
n=51 
M12 
n=51 
 
Total  
 N % n % n % n % 
Age groups (years)          
     30 to 39 11 21.6 12 23.5 12 23.5 35 22.9 
     40 to 49 17 33.3 16 
 
31.4 16 31.4 49 32.0 
     50 to 59 8 15.7 8 15.7 11 21.6 27 17.6 
     60 to 69 12 23.5 15 29.4 8 15.7 35 22.9 
     70 to 79 3 5.9 0 0 4 7.8 7 4.6 
Marital status         
     Single 21 41.2 25 49.0 25 49.0 71 46.4 
     Married 16 31.2 14 27.5 18 35.3 48 31.4 
     Divorced 5 9.8 4 7.8 4 7.8 13 8.5 
    Widowed 9 17.6 8 15.7 4 7.8 21 13.7 
Employment status         
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Unemployed 23 45.1 25 49.0 26 51.0 74 48.4 
Part-time employed 5 9.8 7 13.7 5 9.8 17 11.1 
Full-time employed 14 27.5 11 21.6 11 21.6 36 23.5 
Pensioners 9 17.5 8 15.7 9 17.6 26 17.0 
Stage of the cancer         
IA 2 3.9 1 2.0 0 0 3 2.0 
IB 3 5.9 1 2.0 1 2.0 5 3.2 
IIA 12 23.5 6 11.7 11 21.6 29 19.0 
IIB 14 27.5 16 31.4 9 17.6 39 25.5 
IIIA 8 15.7 15 29.4 17 33.3 40 26.1 
IIIB 11 21.5 12 23.5 13 25.5 36 23.5 
IVA 1 2.0 0 0 0 0 1 0.7 
 
A Kruskal-Wallis H test showed a statistical significance between age and employment status (χ² 
(2) = 46.9, p=0.000), but stage of the disease and employment status had no statistical 
significance. Age and marital status had a statistical significance, (χ² (2) = 23.3, p=0.000), but 
there was no statistical significance between stage of disease and marital status. 
 
4.2 GLOBAL HEALTH STATUS, OVERALL HEALTH AND OVERALL QUALITY OF LIFE 
When calculating the average global health status, overall health and overall quality of life, the 
latter had the highest overall mean score (maximum score 100) (m=70.5). The average global 
health status improved as the months after treatment increased. Similarly, overall health and 
quality of life increased with the lowest mean scores found at m0, improvement at m6 and 
reaching the highest level at m12. A Kruskal-Wallis H test showed a statistically significant 
difference in all three variables amongst the groups (Table 4.2), whilst no statistically significant 
differences were found between the three groups (m0, m6 and m12) and age, marital status, 
employment status and stage of the disease.  
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Table 4.2 Global health status, overall health and overall quality of life during treatment 
(m0) and six (m6) and 12 months after treatment (m12).  
Variables Mean Ranks Overall 
Mean 
SD p 
 m0 
n=51 
m6  
n=51 
m12  
n=51 
   
Global health status 55.1 77.8 98.2 69.9 26.3 0.000* 
Overall health 57.2 77.8 96.1 69.3 26.7 0.000* 
Overall quality of life 55.6 77.8 97.6 70.5 27.5 0.000* 
key =*statistically significant, p≤0.05 
 
4.3 FUNCTIONING SCORES  
Physical, role, emotional, social and cognitive functioning was explored. Role functioning scored 
the highest overall mean (m= 82.0) and social functioning the lowest (m=60.4). Physical 
functioning scored the lowest during treatment at m0 (m=65.8), with social functioning scoring the 
lowest overall mean in m6 (m=79.6) and cognitive functioning in m12 (m=60.4). The mean ranks 
of all five functioning scales improved from m0 to m6. However, there was a decline in means of 
all the functioning scales from m6 to m12 with the exception of emotional functioning. Despite this 
decrease, functioning improved from m0 to m12 in all the domains. None of the functional scores 
showed a statistically significant difference amongst the three groups (Table 4.4).  
 
Table 4.3 Functional scores during treatment (m0) and 6 (m6) and 12 (m12) months after 
treatment (n=153). 
Variables Mean Ranks Overall 
Mean 
SD p  
Functioning scales 
 
m0 
n=51 
m6 
n=51 
m12 
n=51 
   
Role functioning 67.7 81.2 81.1 82.0 22.2 0.146 
Physical functioning 65.8 85.2 80.0 81.8 17.7 0.068 
Cognitive functioning 76.7 83.5 70.8 80.9 21.1 0.312 
Emotional functioning 69.2 80.2 81.6 80.7 22.9 0.289 
Social functioning 74.3 79.6 77.0 60.4 32.9 0.829 
key = *statistically significant, p≤0.05 
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Kruskal-Wallis H tests showed a statistically significant difference between age and physical 
functioning (χ² (2) =3.1, p=0.858), marital status and physical functioning (χ² (2) = 1.7, p=0.635) 
and stage of disease and social functioning (χ² (2) = 2.3, p=0.516). 
 
 
4.4 GENERAL SYMPTOMS  
When exploring the general symptoms of the respondents, financial difficulties scored the highest 
overall mean (m=99.2) and dyspnoea the lowest overall (m=10.5). Fatigue had the highest mean 
score at m0 (m=99.2), pain the highest at m6 (m=78.3) and swelling of the feet at m12 (m=78.3). 
The mean ranks of fatigue, pain, insomnia, dyspnoea and financial difficulties decreased from m0 
to m12, but swelling of the feet and tingling of the hands increased from m0  to m12. Statistical 
significance was found between the three groups (m0, m6 and m12) and various symptoms 
(Table 4.4). 
Table 4.4 General symptoms reported by the respondents on treatment (m0) and at six 
months (m6) and twelve months (m12) after treatment (n=153). 
Variables 
 
Mean Ranks Overall 
Mean 
SD P 
m0  
n=51 
m6  
n=51 
m12  
n=51 
Fatigue 99.2 72.9 58.9 30.0 26.6 0.000* 
Pain 84.4 78.3 63.3 31.5 30.7 0.168 
Insomnia 92.7 73.3 65.1 33.6 39.8 0.002 
Dyspnoea 88.5 76.0 66.5 10.5 21.8 0.003* 
Swelling of feet 61.4 67.6 101.9 16.6 26.2 0.000* 
Tingling of hands or feet 72.4 77.3 81.3 28.3 25.9 0.545 
Financial difficulties 95.2 63.9 71.9 65.1 39.4 0.000* 
key = * statistically significant, p≤0.05 
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When comparing age and stage of the disease with each of the symptoms, the Kruskal-Wallis H 
test revealed no statistically significant differences with the general symptoms. 
 
4. 5 PHYSICAL SYMPTOMS 
Physical symptoms consisted of gastro-intestinal symptoms, urologic and gynaecologic 
symptoms. The variables assessing gastrointestinal symptoms were: appetite loss, diarrhoea, 
constipation, nausea and vomiting. Diarrhoea had the highest overall mean (n=22.6) and nausea 
and vomiting the lowest (n=10.2). During treatment (m0) appetite loss scored the highest mean 
(n=106.2), diarrhoea at m6 (n=79.4) and constipation at m12 (n=79.2). As indicated in Table 4.3 
there was a statistically significant difference between the groups (m0, m6 and m12) and 
diarrhoea, appetite loss and nausea and vomiting.  
 
Table 4.5 Physical symptoms reported by the respondents on treatment (m0) and at six 
months (m6) and twelve months (m12) after treatment (n=153). 
Variables 
 
Mean Ranks Overall 
Mean 
SD P 
m0   
n=51 
m6 
n=51  
m12  
n=51 
Diarrhoea 94.4 79.4 57.3 22.6 31.7 0.000* 
Appetite loss 106.2 60.7 64.0 20.0 29.5 0.000* 
Constipation 83.3 68.6 79.2 14.4 28.3 0.077 
Nausea and vomiting 102.8 65.8 62.4 10.2 24.8 0.000* 
key = * statistically significant, p≤0.05 
 
When comparing age and stage of the disease with each of the physical symptoms, the Kruskal-
Wallis H test revealed no statistically significant differences between physical symptoms, age and 
stage of the disease. 
 
Variables assessing urological symptoms were urine frequency, burning sensation when 
urinating, urine leakage and difficulty emptying the bladder. Urological symptoms persisted across 
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the study groups but presented the highest on treatment (m=90.3), reduced at six months 
(m=63.5), then increased at twelve months (m=77.2).  
 
Table 4.6 Urological symptoms reported by the respondents on treatment (m0) and at six 
months (m6) and twelve months (m12) after treatment (n=153). 
Variables 
 
Mean Ranks Overall 
Mean 
SD P 
m0  
n=51  
m6  
n=51 
m12 
n=51 
Urological symptoms 90.3 63.5 77.2 23.3 18.8 0.008 
Urine frequency 86.2 60.1 83.8 44.9 34.3 0.004 
Burning sensation when 
urinating 
98.3 69.1 67.7 30.5 33.8 0.000* 
Urine leakage 76.2 74.4 80.4 10.5 22.4 0.625 
Difficulty emptying the 
bladder 
80.2 74.1 76.1 7.2 19.1 0.552 
key = * statistically significant, p≤0.05 
 
Kruskal-Wallis H tests showed no statistical significant between age, stage of the disease and all 
the urological symptoms. 
 
Vaginal soreness was reported to have the highest means during treatment but reduced across 
the study groups; the m0 mean was (m=98.5), the m6 (m=75.0) and the m12 (m=57.5). These 
means were statistically significant (p = 0.000).  
 
4.6 GYNAECOLOGIC SYMPTOMS 
Variables for assessing gynaecological symptoms were hot flushes, vaginal discharge and 
vaginal bleeding. The respondents on treatment reported the highest gynaecological symptoms 
with a mean (m=106.1) and marked improvement at m6 (m=68.5) and m12 (m=55.9) as illustrated 
in Table 4.7.  
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Vaginal discharge was most severe during treatment (m=94.3) followed by a marked reduction in 
mean scores at six months (m=69.1) and at twelve months (m=67.7). Vaginal bleeding had the 
highest reported scores in respondents on treatment (m=91.3), followed by a marked decrease 
at six months (m=68.7) then a slight increase at twelve months (m=71.0).  Menopausal symptoms, 
having hot flushes and/or night sweats, did not have any statistical significance across the study 
groups.  
 
Table 4.7 Gynaecological symptoms of respondents on treatment (m0), at six months (m6) 
and twelve months (m12) after radiotherapy (n=153) 
Variables 
 
Mean Ranks Overall 
Mean 
SD P 
m0 
n=51   
m6 
n=51  
m12 
n=51  
Menopausal symptoms (hot 
flushes and/or night 
sweats) 
86.1 72.7 72.2 24.2 27.6 0.151 
Vaginal Discharge 94.3 69.1 67.7  26.2 0.194 
Virginal Bleeding 91.3 68.7 71.0  30.7 0.256 
 
 
4.7 SEXUAL SYMPTOMS 
Slightly more than one third of the respondents (37.3%: n=57) indicated they were sexually active. 
Only 1.3% (n=2) of the respondents indicated they were sexually active during treatment, whilst 
16.3%; (n=25) were sexually active at six months and 19.6%; (n=30) at twelve months post 
radiotherapy. Respondents on treatment had the lowest mean scores in sexual enjoyment as 
reported by the mean (m=56.1) but mean increased to (m=85.3) at six months and (m=91.9) at 
twelve months post radiotherapy. Respondents reported the lowest “sexual worry” mean scores 
at the time of treatment (m=66.5) and had marked increase at six months (m=83.8) and a slight 
drop at twelve months (m= 80.8). However, the results were not statistically significant. Sexual 
activity and enjoyment had significant influence on the quality of life with p = 0.000 as shown in 
Table 4.8 
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Table 4.8 Sexual symptoms of respondents on treatment (m0), at six months (m6) and 
twelve months (m12) after radiotherapy (n=57). 
Variables 
 
Mean Ranks Overall 
Mean 
SD sig* 
m0   
n=2** 
m6  
n=25** 
m12 
n=30** 
Sexual activity  53.7 85.3 91.9 23.1 35.5 0.000* 
Sexual enjoyment 56.1 86.6 88.3 22.0 35.9 0.000* 
Vaginal functioning  52.9 87.6 90.4 14.1 22.8 0.000* 
key = * statistically significant =** n=2,  n=25, n=30 sample size varied because only those who 
were sexually active gave responses for sexually related question. 
 
4.8 SEXUAL FUNCTIONING 
When investigating the factors which influenced sexual activity (Table 4.9), it was found that 
vaginal dryness during sexual activity, the vagina feeling short, tight and painful during sexual 
intercourse was statistically significant. Worry that sex would be painful influenced sexual activity 
at six months and twelve months, but did not influence those on treatment. Vaginal soreness did 
not influence sexual activity across the study groups.  
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Table 4.9 Factors influencing sexual functioning on treatment (m0), six months (m6) and 
twelve months (m12) post radiotherapy (n=57). 
Variables m0 m6 m12 
 p value Df p value Df p value Df 
 Vaginal soreness 0.335 6 0.857 9 0.731 9 
Sexual worry 0.260 6 0.002 9 0.002 9 
 Dry vagina - - 0.000* 9 0.000* 9 
Short vagina 0.000* 2 0.000* 6 0.000* 6 
Tight vagina 0.000* 2 0.000* 9 0.000* 9 
Dyspareunia 0.000* 4 0.000* 9 0.000* 9 
Sexual enjoyment 0.000* 2 0.000* 9 0.000* 9 
key = * statistically significant 
 
The stage of the disease was significant in terms of the social functioning on the group at twelve 
months (p=0.003) and marital status was statistically significant (p=0.001) in terms of the physical 
functioning in the at six and twelve months post radiotherapy. 
 
4.9 SUMMARY   
This chapter provides the findings of the study. The next chapter will discuss the findings and 
recommendations and present the conclusion. 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
 
5.0 INTRODUCTION 
This chapter discusses the findings of the study, justifies the study, considers the limitations and 
recommendations and presents the conclusion. 
 
5.1 DISCUSSION 
The study provided evidence that most of the respondents were between the ages of 40 and 49, 
with a median age of 50.57. The ages of the respondents were relatively similar to the ages of 
patients reported in other studies. Bjelic-Radisic et al. (2012), in a study conducted in 14 countries 
including Australia, Denmark and Germany, found the median age of their sample was 49.7, whilst 
Klee et al. (2000), in a study conducted in Singapore, reported a mean age of 49.3 and Barnas et 
al. (2012), in a Polish study, a mean age of 52.89.  
 
Nearly half the women in the current study (49.9%) presented with advanced disease a finding 
supported by Denny (2012). In addition, considering the ages, stage of disease and the one year 
survival rates of women in the current study, it comes as no surprise that the WHO (2006 states 
most women who die from cervical cancer are in the prime of their lives, raising children, caring 
for their families and contributing to the economy of their communities. 
 
It was positive to find that the global health status, overall health and overall quality of life improved 
significantly during the 12 months after treatment. Pasek et al. (2013), in a study conducted in 
Poland focusing on hospitalised women living with cervical cancer and treated with radiotherapy, 
reported quality of life of the women to be good regardless of the existence of radiotherapy side 
effects. However, physical functioning was the lowest during treatment – which might not be 
strange as patients suffered from acute side effects and cancer related pain. Vaz et al. (2011) 
agreed that pain had a major negative influence on physical functioning. After completion of 
treatment with radiotherapy, acute side effects resolve leading to improvement of cancer related 
symptoms and support care offered to the respondents lead to an increase in physical symptoms 
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and Vaz et al. (2011) alludes to this. Role functioning improved at month 6 and was almost the 
same as at month 12. This could be linked to a decrease in physical symptoms, such as pain and 
reduction of cancer related symptoms in response to treatment, allowing women to resume 
activities of daily living although not to normality. Vaz et al. (2011) supports this finding and 
attributes an improvement in performance status to this phenomenon.  
 
The results of this study showed that respondents on treatment were less emotionally distressed 
compared to those at six months, which contrasted with the findings of Klee et al. (2000), whilst 
Pasek et al. (2012) had similar findings of depreciated emotional functioning at six months post 
radiation treatment. The decrease in emotional functioning could be linked to the respondents’ 
inability to resume normal functioning as per their pre-disease state and this affected their quality 
of life negatively.   
 
Social functioning findings in this study illustrated that respondents on treatment experienced the 
highest negative impact due to cervical cancer. The physical symptoms, such as urine 
incontinence, nausea and vomiting and fatigue, prevented the respondents from participating in 
social activities such as attending social functions, findings that both Pasek et al. (2013) and Klee 
et al. (2000) agree with. At six months and twelve months post radiotherapy, the distressing 
physical symptoms reduced the social functioning improved with a better quality of life.  
 
As seen in the current study, the respondents on treatment experienced financial difficulties as 
they had to attend the hospital for a period of six weeks, five days a week. The study groups at 
six months and twelve months reported a decrease in the financial burden as they had follow-up 
visits once a  month for the first six months followed by a three month’s appointment for the next 
six months. Results of this study on financial difficulties were in agreement with those of Krikeli et 
al.( 2011a), in a study conducted in Greece comparing radiotherapy and radio-chemotherapy 
outcomes in one-year women survivors’ with cervical cancer. 
 
This study’s findings revealed that appetite loss was the most reported symptom affecting the 
gastrointestinal system during the treatment period but which decreased significantly with time. 
Satwant et al. (2014) alludes to these findings, but Klee et al. (2000a) disagreed and indicated 
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that the loss of appetite symptoms were the same throughout their study groups. Diarrhoea 
presented as being highest whilst on treatment and a slight reduction at six months, but lowest at 
twelve months. Klee et al. (2000a) differs, as in their findings only a minority of the respondents 
on treatment reported diarrhoea as being very disturbing. Similar to the study of Klee et al. 
(2000a), the current study found that constipation, nausea and vomiting was highest among the 
respondents undergoing treatment. 
 
The study provided evidence that the most frequently reported symptom, by women treated with 
radiotherapy, was frequent voiding accompanied by soreness and pain, concurring with the 
findings of Klee et al. (2000a). Urine leakage affected quality of life in a minority of respondents 
(3.3%). Pfaendler et al. (2015) reported similar results with 14.6 % cases of urine incontinence. It 
is quite possible that urine leakage led to the women spending most of their time indoors for fear 
of soiling their clothes thus causing embarrassment. In addition, nearly half (48.4%) of the 
respondents were unemployed and may have been unable to buy adult protection to contain the 
leakage.  
 
The study provided evidence that sexual life was the most affected domain, as indicated by 37.3% 
of the total respondents who had been sexually active in the past month (from the time of data 
collection). This may be quite normal as radiotherapy damages the vaginal epithelium, connective 
tissues and small blood vessels causing cell death (Clinical et al. 2012). Complications caused 
by radiotherapy, for example vaginal stenosis, begins three to six months after treatment and 
leads to dyspareunia, lack of lubrication and decreased sexual interest (Maher & Denton 2008). 
Vaginal stenosis leads to additional problems such as inelastic vaginal tissue and the tendency 
to experience pain and bleeding during sexual intercourse (Greimel et al. 2009; Ancuța et al., 
2012). What is going on here?  All these changes compound and cause the women to have 
reduced desire for sex, arousal and orgasm. Experiencing a dry vagina during sexual activity was 
reported amongst the respondents at six months and twelve months post radiotherapy leading to 
pain during sexual activity. This was attributed to a tight vagina, which had stenosed as a result 
of the radiation damage to the vaginal epithelium. The results of this study support similar findings 
by Kumar et al. (2014). 
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Cancer induced fatigue was found to be most worrying amongst respondents in the study, with 
the respondents in need of rest. Goker et al. (2011), in a study conducted in Turkey, also found 
high scores in fatigue. Respondents undergoing radiotherapy reported the highest level of fatigue 
which affected their quality of life as they had to remain in bed or rest on a chair during the day. 
Most respondents reported being able to perform the basic daily activities of daily living, such as 
eating, getting dressed, washing themselves and using the toilet, but were limited in performing 
further strenuous tasks such as carrying heavy shopping baskets and walking long distances. 
 
Swelling of limbs is a late complication and mainly affected the study group at twelve months post 
radiotherapy, findings which were also noted by Bjelic-Radisic et al. (2012). This presents with 
swelling of the lower limbs as a result of the blockage of the lymphatic system of the legs. 
Respondents living with lymphoedema present with swelling of the feet, leg heaviness and 
discomfort, skin texture changes, tight feeling and tingling sensations in the legs limiting the 
women’s ability to perform daily tasks or work thus negatively affecting their quality of life 
(Pfaendler et al. 2015). In contrast, the respondents on treatment reported the lowest mean 
scores and a slight increase in those at six months as the signs of lymphoedema began to present. 
Similar findings were observed by Bjelic-Radisic et al. (2012).  
 
5.2 JUSTIFICATION OF THE STUDY 
The purpose of the study was to explore the quality of life of women treated for cervical cancer. 
The study aimed to explore the quality of life of women diagnosed with cervical cancer and 
currently being treated with radiotherapy, at six months after completion of treatment and at twelve 
months after treatment at an academic hospital in Gauteng and to compare with the quality of life 
of these three groups of women 
 
In Chapter 3, the research design and methods were described in detail, Chapter 4 presented the 
results which included comparisons between the three groups and Chapter 5 discussed the 
results also referring to the time since treatment. It can therefore be stated that this study is 
justified as the purpose and aims were met.  
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5.3 LIMITATIONS OF STUDY 
The researcher selected a cross sectional design which did not allow for the exploring of changes 
in the same respondents over time. A longitudinal design may have resulted in more accurate 
findings; however the researcher believes the study provided base line data regarding the quality 
of life of women treated for cervical cancer. 
 
5.4 RECOMMENDATIONS 
According to the findings of the study, interventions ought to be put in place by nurses practicing 
in cancer care settings to address the physical,  role, social and emotional functioning with the 
aim of improving the quality of life for women treated for cervical cancer. For example; the public 
can be educated on the importance of screening to be able to diagnose cervical cancer in the 
early stages when cure rate is high and negative effects of the cancer on the quality of life is 
minimal. Providing effective symptom support care for cervical cancer patients receiving treatment 
and those on follow up could also be of benefit. Further studies should be conducted and a 
longitudinal design used to enable the exploration of changes in the same respondents. 
 
5.5 CONCLUSION 
In conclusion, the overall quality of life was affected by cancer related symptoms and acute side 
effects of radiotherapy treatment leading to low mean scores while on treatment but this improved 
at six and twelve months in response to radiotherapy and resolving of the acute side effects. 
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ENGLISH 
EORTC QLQ-C30 (version 3) 
 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will remain 
strictly confidential. 
Please fill in your initials:                          _ _ _ _ 
Your birthdate (Day, Month, Year):          _ _  _ _  _ _ _ _ 
Today's date (Day, Month, Year):             _ _  _ _  _ _ _ _ 
__________________________________________________________________________________________ 
                                                                                                                                   Not at    A      Quite    Very 
                                                                                                                                     All     Little   a Bit    Much 
1. Do you have any trouble doing strenuous activities, 
like carrying a heavy shopping bag or a suitcase?                                                   1          2           3          4 
 
2. Do you have any trouble taking a long walk?                                                        1         2           3          4 
 
3. Do you have any trouble taking a short walk outside of the house?                     1           2          3         4 
 
4. Do you need to stay in bed or a chair during the day?                                          1            2          3        4 
 
5. Do you need help with eating, dressing, washing 
yourself or using the toilet?                                                                                       1           2           3       4 
 
During the past week:                                                                                          Not at      A      Quite   Very 
                                                                                                                                   All       Little   a Bit    Much 
6. Were you limited in doing either your work or other daily activities?                      1         2         3          4 
 
7. Were you limited in pursuing your hobbies or other 
leisure time activities?                                                                                                 1         2         3          4 
 
8. Were you short of breath?                                                                                       1         2         3         4 
 
9. Have you had pain?                                                                                                 1          2        3         4 
    
10. Did you need to rest?                                                                                             1          2       3          4 
 
11. Have you had trouble sleeping?                                                                             1          2       3         4 
 
12. Have you felt weak?                                                                                               1          2        3        4 
 
13. Have you lacked appetite?                                                                                     1          2       3         4 
 
14. Have you felt nauseated?                                                                                       1          2        3        4 
 
15. Have you vomited?                                                                                                 1          2        3         4 
 
16. Have you been constipated?                                                                                  1          2        3        4 
 
Please go on to the next page 
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 ENGLISH 
During the past week:                                                                                              Not at    A     Quite     Very 
                                                                                                                                     All     Little   a Bit    Much 
17. Have you had diarrhea?                                                                                           1          2           3           4 
 
18. Were you tired?                                                                                                        1          2          3           4 
 
19. Did pain interfere with your daily activities?                                                              1          2          3           4 
 
20. Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television?                                                          1          2          3           4 
 
21. Did you feel tense?                                                                                                   1          2          3          4 
 
22. Did you worry?                                                                                                          1          2          3          4 
 
23. Did you feel irritable?                                                                                                1          2          3           4 
 
24. Did you feel depressed?                                                                      1          2          3          4 
 
25. Have you had difficulty remembering things?                                                           1          2          3          4 
 
26. Has your physical condition or medical treatment 
interfered with your family life?                                                                                        1          2          3          4 
27. Has your physical condition or medical treatment 
interfered with your social activities?                                                                                1          2          3          4 
28. Has your physical condition or medical treatment 
caused you financial difficulties?                                                                                      1           2          3          4 
 
For the following questions please circle the number between 1 and 7 that 
best applies to you 
29. How would you rate your overall health during the past week? 
         1               2                 3                4               5               6               7 
   Very poor                                                                                          Excellent 
30. How would you rate your overall quality of life during the past week? 
       1               2                 3                 4                 5                6                7 
   Very poor                                                                                              Excellent 
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APPENDIX B: EORTC QLQ – CX24 
 
ENGLISH 
EORTC QLQ – CX24 
 
Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you 
have experienced these symptoms or problems, please answer by circling the number that best applies to you. 
 
During the past week:                                                                                         Not       A       Quite        Very 
                                                                                                                             at all    little     a bit         much 
31. Have you had cramps in your abdomen?                                                          1          2            3              4 
 
32. Have you had difficulty in controlling your bowels?                                            1          2            3             4 
 
33. Have you had blood in your stools (motions)?                                                   1          2            3             4 
 
34. Did you pass water/urine frequently?                                                                 1           2           3              4 
 
35. Have you had pain or a burning feeling when passing water/urinating?            1         2            3             4 
 
36. Have you had leaking of urine?                                                                          1          2            3             4 
 
37. Have you had difficulty emptying your bladder?                                                 1           2           3             4 
 
38. Have you had swelling in one or both legs?                                                       1           2           3             4 
 
39. Have you had pain in your lower back?                                                             1           2           3              4 
 
40. Have you had tingling or numbness in your hands or feet?                               1           2            3             4 
 
41. Have you had irritation or soreness in your vagina or vulva?                            1           2            3             4 
 
42. Have you had discharge from your vagina?                                                      1           2           3              4 
 
43. Have you had abnormal bleeding from your vagina?                                        1           2           3              4 
 
44. Have you had hot flushes and/or sweats?                                                         1          2             3             4 
 
45. Have you felt physically less attractive as a  
result of your disease or treatment?                                                                         1           2            3              4 
46. Have you felt less feminine as a  
result of your disease or treatment?                                                                          1          2            3             4 
47. Have you felt dissatisfied with your body?                                                           1          2            3            4 
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  ENGLISH 
 
During the past 4 weeks:                                                                                      Not        A     Quite      Very 
                                                                                                                               at all     little    a bit      much 
48. Have you worried that sex would be painful?                                                        1          2          3           4 
 
49. Have you been sexually active?                                                                            1          2          3           4 
 
 
Answer these questions only if you have been                                                  Not       A      Quite       Very 
sexually active during the past 4 weeks:                                                            at all     little    a bit       much 
 
50. Has your vagina felt dry during sexual activity?                                                   1         2          3             4 
 
51. Has your vagina felt short?                                                                                   1         2          3            4 
 
52. Has your vagina felt tight?                                                                                    1         2          3            4 
 
53. Have you had pain during sexual intercourse or other sexual activity?                1         2          3            4 
 
54. Was sexual activity enjoyable for you?                                                                  1         2          3           4 
 
 
 
 
 
 
 
 
 
 
© QLQ-CX24 Copyright 2003 EORTC Quality of life Group. All rights reserved. (phase III module) 
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APPENDIX C:QLQ-C30 download request from Caroline Sabulei 
qlqc30@eortc.be 
May 13, 2014 
Tome  
  
Dear Sir/Madam, 
 
Please find below the links where you can download the documents you requested. 
Best regards, 
 
Your data: 
Title: Mrs 
First name: caroline 
Last name: sabulei 
Hospital/Institution: University of Witwatersrand 
Address: Private Bag 3 
County/State: Gauteng 
Postal Code: 2050 
Country: South Africa 
Phone: +27748024038 
Fax: N/A 
Email: csabulei@ymail.com 
Protocol: Quality of life of women living with cervical cancer 
Documents requested: 
QLQ-C30 Core Questionnaire in English  
Cervix Module (CX24) in English  
QLQ-C30 Scoring Manual 
Full reference values 
Latest issue of the EORTC Quality of Life Group Newsletter 
Scoring Instructions: Cervix CX24 
URLs: 
http://www.eortc.be/qol/files/C30/QLQ-C30%20English.pdf 
http://www.eortc.be/qol/files/CX24/CX24%20English.pdf 
http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf 
http://www.eortc.be/qol/files/RV/RV_complete.pdf 
http://www.eortc.be/qol/files/QOL_newsletter.pdf 
http://www.eortc.be/qol/files/ScoringInstructions/CX24_summary.pdf 
 
If the links don't work, you can copy and paste the entire URL (so with .pdf included) into your 
browser and that should work. If you are having other technical difficulties please contact us by 
email: qlqc30@eortc.be 
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APPENDIX D: DATA COLLECTION TOOL 
 
AN EXPLORATION INTO THE QUALITY OF LIFE OF WOMEN TREATED FOR CERVICAL 
CANCER AT AN ACADEMIC HOSPITAL IN GAUTENG, SOUTH AFRICA. 
DATA COLLECTION TOOL 
SECTION 1: DEMOGRAPHIC DATA 
 
1.1 Age (Years)            
 
1.2  Stage of Cervical cancer     
 
1.3 Marital Status 
  
Single  
Married  
Divorced  
Widowed  
 
1.4 Employment Status 
 
Unemployed  
Part time employed  
Full time employed  
Pensioner  
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APPENDIX E: PERMISSION TO CONDUCT RESEARCH 
 
University of the Witwatersrand 
Faculty of Health Sciences 
Department of Nursing Education 
7 York Road,  
Parktown 2193 
 
Gauteng Department of Health/CEO of the Charlotte Maxeke Johannesburg Academic Hospital 
Dear Madam /Sir, 
RE: PERMISSION TO CONDUCT RESEARCH 
My name is Caroline Sabulei, a student at the University of the Witwatersrand, Johannesburg. I 
am currently registered for Master of Science in Oncology and Palliative Care Nursing in the 
Department of Nursing Education. I am hereby asking for permission to undertake a study at 
Charlotte Maxeke Johannesburg Academic Hospital. I am investigating “The quality of life in 
cervical cancer patients treated with radiotherapy”. 
The purpose of this study is to gain an understanding of the experiences of women undergoing 
radiotherapy treatment for cervical cancer. This study will contribute to the provision of holistic 
care to women and after the treatment. Participation to this study is completely voluntary and 
confidential. The participants name will not appear anywhere and only initials of names will be 
used. The questionnaires will be filled by consenting patients in the radiology department and will 
take about fifteen minutes of the patients’ time. 
The information will be used for the intended purpose only. The participants may discontinue 
participation at any time of the study without any penalty or loss of benefits to which they are 
otherwise entitled. An informed written consent will be obtained from all participants to be included 
in the study. Participants who sign the consent will indicate acceptance to participate in the study.  
I hope to conduct this study in the radiation oncology out-patients department where women come 
for clinics and in the oncology ward for those who are undergoing treatment. The name of the 
participating Hospital and patients involved will not be divulged in the research report. Ethical 
clearance has been obtained from the Human Research Ethics Committee of the University of 
the Witwatersrand. Find attached copy of my research proposal as well as the ethical clearance. 
Thanking you in advance for allowing me to conduct the study. Your permission is valuable and 
highly appreciated. 
Yours faithfully 
Caroline Sabulei (MSc Nursing Student)  Date…………………………………. 
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APPENDIX F: INFORMATION DOCUMENT 
 
Study title: QUALITY OF LIFE IN CERVICAL CANCER PATIENTS TREATED WITH 
RADIOTHERAPY AT AN ACADEMIC HOSPITAL IN GAUTENG, SOUTH AFRICA. 
Good day Madam, 
My name is Caroline Sabulei. I am currently registered as a student in the Department of Nursing 
Education at the University of the Witwatersrand and would like to conduct a study entitled “The 
quality of life in cervical cancer patients treated with radiotherapy”.I would like to invite you 
to consider participating in this research study where I would use the words that people tell me. If 
you should you agree to take part in the study, I will provide you with a questionnaire for you to 
fill and will take about 15 minutes. The study will take place at the oncology ward for those who 
are in-patients and at the oncology clinic for the out-patients in a quiet and private place. 
There are no direct benefits to you as the participant. However, the findings will assist nurses to 
identify and manage patient problems based on their needs. Should you decide not to participate 
in the study, you will not lose any benefit to which you are entitled. Even if you decide to take part 
in the study, you may at any time choose to withdraw and you will not lose any benefits to which 
you are entitled. However, upon filling the questionnaire, I will not be able to identify your 
questionnaire as only the initials of your name are used. This means you would not be able to 
withdraw from the study any more. Also, please note that you will not receive any money or goods 
should you choose to take part in the study. I will keep information confidential. Personal 
information may be made known if the law says so, research records may be inspected to look at 
the quality and the Research Ethics Committee can inspect how I analyzed what you told me. 
After analyzing the information, all data sheets will be sealed in an envelope and placed in a safe 
in the Department of Nursing Education for a period of three years after the report has been 
published where after it will be destroyed. When I write a report on what all the women filled in no 
names or initials will be referred to. People who will read the report would however not know that 
this is what you said. If you have any question, or further information about the study, do not 
hesitate to contact me, my cell phone number is 0612298264.Should you have any question about 
your rights as a study participant, or questions concerns about any aspect of this study, please 
call the Ethics Department of the University of the Witwatersrand on +27 11 717 1234 or my Head 
of Department, Prof J E Maree at 011 488 4272. 
Thank you for your consideration. 
……………………… 
Caroline Sabulei. 
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APPENDIX G: CONSENT FORM 
I have been given the information sheet on the research Title: “The quality of life in cervical 
cancer patients treated with radiotherapy”. I have read and understood the information sheet. 
If I agree to participate in the study, I will be asked to fill two (2) questionnaires which takes about 
fifteen (15) minutes about the quality of my life during or after the cervical cancer treatment with 
radiotherapy. 
I understand that it is up to me whether or not to participate in study and that there will be no 
penalty or loss of benefits am entitled if I decide not to participate. I also understand that I may 
discontinue participation at any time the study with no penalty or loss of benefits to which am 
otherwise entitled.  
I understand that the researcher involved in this study will make every effort to ensure 
confidentiality and my name will not be used in the study reports. No identifying information will 
be included when the questionnaires are analyzed. I have been given the contact details that I 
may call if I have any questions or concerns about the research. 
This study has been explained to me. I have read and understand this consent form, I agree 
voluntarily to participate in the interview for this study. 
 
……………………………………                                               ………..................... 
Signature of participant                                                                   Date 
 
………………………………                                                         ……………….…….. 
Witness                                                                                                  Date 
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APPENDIX H: ETHICS CLEARANCE CERTIFICATE 
 
 
